J9289 Injection nivolumab 2 milligrams hyaluron
Also known as: nivolumab hyaluronidase, Opdivo subcutaneous
Injection of nivolumab combined with hyaluronidase, 2 milligram. A PD-1 checkpoint inhibitor with enhanced subcutaneous delivery formulation.
In Plain Language
immunotherapy injection; cancer immune checkpoint drug
Clinical Context
Subcutaneous formulation of nivolumab used for melanoma, non-small cell lung cancer, renal cell carcinoma, and other malignancies.
RVU Information
CPT J9289 does not have a physician work RVU assigned by CMS. This is typical for supply, drug, and equipment codes — reimbursement is based on Average Sales Price (ASP), fee schedules, or payer contracts rather than the RVU system.
Billing & Documentation
J-codes represent drugs administered by a healthcare provider (not self-administered). Documentation must include the drug name, dosage, route of administration, and medical necessity. Most payers require the National Drug Code (NDC) on the claim. Bill the appropriate administration code (96365-96379) in addition to the drug code.
Specialties
Frequently Asked Questions
What is CPT code J9289?
CPT J9289 (Injection nivolumab 2 milligrams hyaluron) is a J Codes (Drugs) code. Injection of nivolumab combined with hyaluronidase, 2 milligram. A PD-1 checkpoint inhibitor with enhanced subcutaneous delivery formulation.
How is J9289 administered?
CPT J9289 is administered by a healthcare provider, typically via injection or infusion. Subcutaneous formulation of nivolumab used for melanoma, non-small cell lung cancer, renal cell carcinoma, and other malignancies. It is used by Oncology, Pulmonology, Dermatology.
When is CPT J9289 used?
Subcutaneous formulation of nivolumab used for melanoma, non-small cell lung cancer, renal cell carcinoma, and other malignancies.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.